ReviewPharmacological research2021
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.
Review in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis.BioMed research international · 2022Pooled it
- Review
- Elevated Lipoprotein(a) Is Highly Prevalent in Autoimmune or Inflammatory Disease: A Multisite Study.JACC. Advances · 2026Article
- Lipoprotein(a) -Related Cognitive Vulnerability After Stroke Beyond High-Sensitivity C-Reactive Protein.Translational stroke research · 2026Article
- The Role of Serum Biomarkers for the Differential Diagnosis and Prognostic Assessment of Myocardial Infarction with Non-Obstructive Coronary Arteries: A Narrative Review.Journal of clinical medicine · 2026Review
- Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a).Cardiovascular & hematological disorders drug targets · 2026Review
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- From lipid dysbalance to cardiorenal decompensation: apoB/ApoA1 ratio is associated with acute cardiorenal injury in CAD patients.Frontiers in cardiovascular medicine · 2026Article
- Serum lipoprotein(a) and risk of contrast-induced nephropathy in patients with type 2 diabetes mellitus.Frontiers in cardiovascular medicine · 2026Article
- Elevated serum lipoprotein(a) as a prognostic marker for reduced survival in pancreatic cancer.BMC gastroenterology · 2025Article
- Article
- Systemic inflammation modulates lipoprotein(a)-associated coronary stenosis in the chronic coronary syndromes.American journal of preventive cardiology · 2025Article
- Lipoprotein(a) and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.European heart journal · 2025Article
- Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Microbiome and metabolic disorder in prolactinoma: intrinsic gender differences and extrinsic therapy effects.Pituitary · 2025Article
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- The Association between Lipoprotein(a) and Coronary Artery Calcification in Elderly Patients with Diabetes: A Cross-Sectional Study.Reviews in cardiovascular medicine · 2025Article
- Synergistic effects of lipoprotein (a) and fibrinogen on carotid plaque in patients with coronary artery disease.European journal of medical research · 2025Article
- Lipoprotein(a) molar concentrations rather than genetic variants better predict coronary artery disease risk and severity in Han Chinese population.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Genome wide association, epidemiological, and clinical studies have established high lipoprotein(a) [Lp(a)] as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is an apoB100 containing lipoprotein covalently bound to apolipoprotein(a) [apo(a)], a glycoprotein. Plasma Lp(a) levels are to a large extent determined by genetics. Its link to cardiovascular disease (CVD) may be driven by its pro-inflammatory effects, of which its association with oxidized phospholipids (oxPL) bound to Lp(a) is the most studied. Various inflammatory conditions, such as rheumatoid arthritis (RA), systemic lupus erythematosus, acquired immunodeficiency syndrome, and chronic renal failure are associated with high Lp(a) levels. In cases of RA, high Lp(a) levels are reversed by interleukin-6 receptor (IL-6R) blockade by tocilizumab, suggesting a potential role for IL-6 in regulating Lp(a) plasma levels. Elevated levels of IL-6 and IL-6R polymorphisms are associated with CVD. Therapies aimed at lowering apo(a) and thereby reducing plasma Lp(a) levels are in clinical trials. Their results will determine if reductions in apo(a) and Lp(a) decrease cardiovascular outcomes. As we enter this new arena of available treatments, there is a need to improve our understanding of mechanisms. This review will focus on the role of Lp(a) in inflammation and CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.